Hyundai Bioscience Co

Hyundai Bioscience Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Hyundai Bioscience Co (048410.KQ) as of Nov 3, 2026 is -31.02. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 13,207.16 — a change of -100.23% (lower).

EV/FCF

-31.02

YoY

-100.23%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Hyundai Bioscience Co is 2025 -31.02 . EV/FCF (Enterprise Value to Free Cash Flow) of Hyundai Bioscience Co was 2024 13,207.16 . It decreases by -100.23% lower compared to the previous year.

The Hyundai Bioscience Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-563.28 KRW
Jan 1, 2019
190.03 KRW
Jan 1, 2020
-66.28 KRW
Jan 1, 2021
-267.10 KRW
Jan 1, 2022
-63.19 KRW
Jan 1, 2023
-175.16 KRW
Jan 1, 2024
13,207.16 KRW
Jan 1, 2025
-31.02 KRW
The Hyundai Bioscience Co EV/FCF history
YEAREV/FCFYoY
-31.02-100.23%
13,207.16-7,639.96%
-175.16+177.21%
-63.19-76.34%
-267.10+302.99%
-66.28-134.88%
190.03-133.74%
-563.28+149.15%
-226.08+118.67%
-103.39-94.99%
-2,064.96-168.34%
3,021.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyundai Bioscience Co Stock analysis

What does Hyundai Bioscience Co do? Hyundai Bioscience Co., Ltd. generates revenue through the manufacturing and sale of bio-cosmetics and hair tonics, including functional daily necessities like shampoos, mask packs, and creams. The company also develops tumor-targeted drugs and sells LCD monitors and digital signage display products. Domestic and overseas markets, including Europe, America, and Japan, purchase these products, with the firm distributing its offerings across these regions. The company's product portfolio features bio-cosmetics, hair tonics, shampoos, mask packs, creams, tumor-targeted drugs, LCD monitors, and digital signage displays. These items are sold to customers in both domestic and international markets, with Europe, America, and Japan representing key overseas segments. The firm focuses on functional daily necessities and display technology products as its core revenue streams. Hyundai Bioscience Co., Ltd. targets consumers seeking bio-based personal care products and businesses requiring display solutions. Its domestic market serves local customers, while international segments in Europe, America, and Japan drive global sales. The company’s revenue model combines consumer goods sales with technology-oriented product distribution. Hyundai Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyundai Bioscience Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Hyundai Bioscience Co is -31.02 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Hyundai Bioscience Co changed from 13,207.16 to -31.02, representing a -100.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Hyundai Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Hyundai Bioscience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Hyundai Bioscience Co

All Key Metrics — Hyundai Bioscience Co